VRTX240802P495000
- 6.75
- -1.82-21.24%
Vertex Pharmaceuticals Newsroom
REGENXBIO Releases New Data on DMD Drug Ahead of Earnings
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
Meta, Arm, Qualcomm, Carvana, Teladoc, Apple, Amazon, and More Stock Market Movers
Vertex Pharmaceuticals Q2 2024 Earnings Preview
14 Analysts Assess Vertex Pharmaceuticals: What You Need To Know
Vertex Pharmaceuticals Is Maintained at Sell by Canaccord Genuity
Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $376
CCORF Maintains Vertex Pharmaceuticals(VRTX.US) With Sell Rating, Raises Target Price to $376
PepGen Stock Tumbles 25% Following Release of DMD Drug Data
Form 144 | Vertex Pharmaceuticals(VRTX.US) Officer Proposes to Sell 7.68 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 30, $Vertex Pharmaceuticals(VRTX.US)$ Officer Kewalramani Reshma intends to sell 15,202 shares of its common stock on Jul 30, with a total market value of approximately $7.
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Vertex Pharmaceuticals' New Drug Application Submission for Suzetrigine Gets FDA Pass
Express News | Vertex Pharmaceuticals Inc - FDA Grants Priority Review and Assigns a Prescription Drug User Fee Act (Pdufa) Target Action Date of January 30, 2025
Express News | Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain
Canaccord Genuity Adjusts Price Target on Vertex Pharmaceuticals to $376 From $371
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $545
Buy Rating Affirmed for Vertex Pharmaceuticals Amid Promising Pain Management and Cystic Fibrosis Developments
Russell Top 200 Stocks With Positive Implied Growth + Positive Expected Surprises - Citi
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
Express News | Vertex Pharmaceuticals Inc : Leerink Partners Raises Target Price to $545 From $529